Clinical Trial

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

Name: A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease — clinical trial record (NCT07737743)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection for Phase 3.

Trial Details

NCT Number	NCT07737743
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Sjögren's Disease
Enrollment	344 participants
Start Date	2026-08-27
Primary Completion	2029-02-19 (estimated)
Study Completion	2029-03-19 (estimated)
Updated on ClinicalTrials.gov	2026-07-30